US Pharma MarketingBial bails after Parkinson’s fail, axing asset over phase 2 miss
Bial has stopped developm Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.
Source: FierceBiotech